A busy earnings week is dominating trader attention. Ulta Beauty kicks off Monday, with Dollar General, Macy's, and PVH Corp following Tuesday. Investors will read each print closely for clues on US consumer health. Medtronic reports Wednesday with analysts already trimming targets — a tough setup heading into the print.
Options traders are siding with bulls ahead of two key June 3 prints. Rubrik call buyers have taken control of the room. SAIC hit a year-low put/call ratio ahead of its own results. Meanwhile, short sellers are moving the other way on — short interest jumped 21% in a week to 23.5% of free float, with borrow availability nearly exhausted.
Revolution Medicines grabbed headlines with news of an experimental pill showing promise against pancreatic cancer. The AP report carries a high impact score. It could be a meaningful catalyst for the stock.
On the insider front, board-linked selling at CVS Health and Twilio topped $300M each this week. Hedge fund manager Lawrence Robbins filed over $315M in CVS sales. Twilio board member Andy Stafman filed $314M in total sales in May.
European stocks are sliding. Defence names are rallying after Ukraine ratified a $105 billion EU loan deal. The Dulux maker AkzoNobel surged after rejecting a $14.5 billion takeover bid from a rival.
Chevron's CEO warned oil prices could spike over summer. Up to 13 million barrels per day have been removed from global markets due to the Hormuz blockade. Gold miners like Newmont are well-placed if inflation worries grow. Analysts lifted the consensus target on NEM to $143.05 this week.
SpaceX IPO buzz is intensifying. Net $14 billion has poured into funds with SpaceX exposure. Multiple ETF providers are lining up products. The rush signals strong retail and institutional appetite.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
